Edition:
United Kingdom

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

744.00DKK
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
kr.744.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,210
52-wk High
kr.1,133.00
52-wk Low
kr.681.00

Latest Key Developments (Source: Significant Developments)

ALK-Abello Provides Pricing In New Share Issue
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Alk-Abello A/S ALKb.CO::PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S.- ON 11 DECEMBER 2017 ALK WILL ISSUE A TOTAL OF 92,076 NEW AA SHARES AND 920,760 NEW B SHARES AT DKK 690 PER SHARE.OFFERING RESULTING IN GROSS PROCEEDS FOR ALK IN THE AMOUNT OF DKK 698,856,840.  Full Article

Alk-Abelló to issue shares in private placement
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - ALK-ABELLO A/S ::ALK-ABELLÓ A/S TO ISSUE UP TO 92,076 AA SHARES AND UP TO 920,760 B SHARES IN A PRIVATE PLACEMENT.  Full Article

ALK-Abello To Invest Around DKK 1 Bln In North America​
Monday, 4 Dec 2017 

Dec 4 (Reuters) - ALK-ABELLO A/S ::‍WILL INVEST APPROXIMATELY DKK 1 BILLION TO SUCCEED IN NORTH AMERICA​.‍2018 REVENUE IS EXPECTED TO BE SLIGHTLY BELOW 2017​.‍AFTER 2018, ALK EXPECTS TO DELIVER ORGANIC REVENUE GROWTH OF 10% OR MORE ANNUALLY​.OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION.SAYS ‍NEW FINANCING IS EXPECTED TO COVER A PROJECTED ACCUMULATED NEGATIVE FREE CASH FLOW OF DKK 1 BILLION​.CONTINUES TO EXPECT FULL-YEAR REVENUE AT AROUND DKK 2.9 BILLION AND OPERATING PROFIT OF DKK 225-250 MILLION.‍OVER NEXT FIVE YEARS, ANNUAL TOTAL RESEARCH AND DEVELOPMENT COSTS ARE EXPECTED TO BE IN RANGE OF DKK 400-600 MILLION​.‍WILL POSITION ITSELF TO PENETRATE NON-AIT MARKET​.  Full Article

Alk-Abello Q3 EBITDA falls to DKK 36 million
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ALK-ABELLO A/S :Q3 TOTAL REVENUE DKK ‍667​ MILLION VERSUS DKK 630 MILLION YEAR AGO.‍FINANCIAL GUIDANCE FOR FULL-YEAR REVENUE HAS BEEN NARROWED WHILE GUIDANCES FOR OPERATING PROFIT (EBITDA) AND FREE CASH FLOW REMAIN UNCHANGED​.‍FULL-YEAR REVENUE IS NOW PROJECTED AT APPROXIMATELY DKK 2.9 BILLION (PREVIOUSLY DKK 2.8-3.0 BILLION)​.Q3 ‍OPERATING PROFIT (EBITDA) WAS DKK 36 MILLION (110) FOLLOWING PLANNED COST INCREASES TO SUPPORT LONG-TERM GROWTH​.‍2017 OPERATING PROFIT (EBITDA) IS STILL EXPECTED TO BE DKK 225-250 MILLION.​.2017 ‍FREE CASH FLOW IS STILL EXPECTED AT APPROXIMATELY MINUS DKK 700 MILLION.​.REUTERS POLL: Q3 TOTAL REVENUES DKK 677 MILLION, GROUP EBIT LOSS DKK 22.5 MILLION ‍​.  Full Article

ALK-Abello says Jupiter Asset Management reduced ownership in ALK to below 5 pct of share capital​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - ALK-Abello A/S - :‍Received notification from Jupiter Asset Management, that Jupiter reduced ownership in ALK to below 5% of share capital​.  Full Article

Alk-Abello acts on French injunction
Friday, 22 Sep 2017 

Sept 22 (Reuters) - ALK-ABELLO A/S :ALK-ABELLO A/S - FRENCH NATIONAL AGENCY FOR MEDICINES AND HEALTH PRODUCTS SAFETY ISSUED INJUNCTION AGAINST ALK.ALK-ABELLO A/S - INJUNCTION ISSUED AGAINST ALK LINKED TO NEEDED UPGRADES OF QUALITY SYSTEM AT ITS MANUFACTORING FACILITY IN VANDEUIL.ALK HAS TEMPORARILY STOPPED PRODUCTION IN STERILE AREA AND HALTED RELEASE OF ALL PRODUCTS MANUFACTURED THERE.ALK-ABELLO - ANSM INSTRUCTED CO TO MAKE QUALITY IMPROVEMENTS TO FACILITY, PREDOMINANTLY STRENGTHENING OF ENVIRONMENTAL MONITORING, DEVIATION HANDLING.ALK-ABELLO A/S - AS PRECAUTIONARY MEASURE, CO HAS INITIATED RECALL OF ALL INJECTABLE SCIT PRODUCTS RELEASED FROM AFFECTED AREA SINCE MARCH 2017.ALK-ABELLO A/S - TEMPORARY HALT IN PRODUCTION WILL LEAD TO SCIT PRODUCTS AND SKIN PRICK TESTS BEING IN SHORT SUPPLY UNTIL SITUATION IS FULLY REMEDIED.ALK EXPECTS ONLY A LIMITED, NEGATIVE SPILL-OVER EFFECT ON SALES OF OTHER PRODUCTS.EXPECTS THAT SUSPENSION WILL HAVE A SLIGHTLY NEGATIVE EFFECT ON ITS FULL-YEAR REVENUE.EXPECTS EXTRA COSTS ASSOCIATED WITH NEEDED UPGRADE OF QUALITY SYSTEM.2017 FULL-YEAR GUIDANCE REMAINS UNCHANGED.  Full Article

Alk Abello Q2 EBIT DKK 119 million, beats expectations
Tuesday, 16 Aug 2016 

Alk Abello A/S : Q2 total revenue 773 million Danish crowns ($116.5 million)(Reuters poll 688 million crowns) . Q2 EBIT 119 million crowns (Reuters poll 88.6 million crowns) . Updated guidance to reflect H1 2016 performance and a higher than expected order intake in Europe . Guidance assumes 5-10 pct organic growth in base business in H2 2016 and a minor contribution from partnerships . Free cash flow is now expected at 50-100 million crowns (previously better than in 2015) . Full-year revenue in base business is now expected to grow organically by approximately 20 pct (previously: 15 pct) . Full-year revenue is now projected to exceed 2.9 billion crowns .Full-year EBITDA is now expected to exceed 600 million crowns before special items.  Full Article

Merck plans to end partnership agreement with Alk Abello
Wednesday, 27 Jul 2016 

Alk Abello A/S : Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement . Said all rights to GRASTEK, RAGWITEK and investigational house dust mite SLIT-tablets for USA, Canada and Mexico to revert to ALK at no fee following six- month transition period . Ongoing registration processes for investigational HDM SLIT-tablet will continue . North America remains major business opportunity and ALK will now undertake full strategic analysis before deciding on revised strategy . Transaction has no impact on ALK's full-year outlook for 2016 .Acting CEO and Chairman Steen Riisgaard said: "The timing of this move is unexpected".  Full Article

Alk Abello: Member of Management Board sells shares worth DKK 2.7 million
Friday, 20 May 2016 

Alk Abello A/S :Flemming Pedersen, Member of Board of Management, sold on May 20 a total of 2,191 Alk Abello shares at market value 2.7 million Danish crowns ($407,689).  Full Article

ALK-Abello names Carsten Hellmann new CEO
Wednesday, 18 May 2016 

ALK-Abello A/S : Said on Tuesday Board of Directors had appointed Carsten Hellmann as new President and Chief Executive . Hellmann is currently CEO of Merial and Executive Vice President and member of the Executive Committee of Sanofi .Hellmann to take up CEO position no later than Jan. 1, 2017.  Full Article

BRIEF-ALK-Abello Provides Pricing In New Share Issue

* PRESS RELEASE PRICING AND FURTHER DETAILS ON THE OFFERING OF NEW SHARES IN ALK-ABELLÓ A/S